NEW YORK, May 26, 2011 /PRNewswire/ -- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics,
Lpath's president and CEO, Scott Pancoast, will discuss the company's progress, including status updates on the PEDigree and Nexus clinical trials, where the company's ocular drug candidate, iSONEP™, is being investigated in human proof-of-concept studies.
To access, follow this link: www.retailinvestorconferences.com and then click on: "Register/Watch Event Now!" Attendees are advised to pre-register and receive event updates.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time in the virtual "presentation hall." After the presentation investors are invited to ask questions and download shareholder materials from the company's "virtual booth." A replay of the event will be available for 90 days.
Lpath entered into an agreement with Pfizer in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for ocular indications. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.
Pfizer also has a right of first refusal, which expires in late 2013, for Lpath's cancer drug candidate, ASONEP™. Lpath is planning to further investigate ASONEP in a Phase 2 trial involving renal cell carcinoma patients and perhaps in a second trial involving patients with prostate cancer or neuroblastoma.
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.
RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company's drug programs; the eventual revenues that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for iSONEP may not be favorable and the Company may never receive regulatory approval for iSONEP; and the Company may not be able to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SOURCE Lpath, Inc.
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All